Epstein Secrets

lable USA Cleantech Fund #1 $35M ■ $25M Institutional ■ 16 Units @ $625K/Unit ■ Available DACART CAPITAL LLC EFTA_R1_01138806 EFTA02295532 David Carter, Managing Director • 25+ years executive-level experience • Chairman, CEO/President - 7 companies • Co-founder - 3 companies • 3 M&A's, 1 IPO •

cals business from 2000 to 2003. Prior to joining SmithKline Beecham plc Mr. Pien worked for six years at Abbott Laboratories and for five years at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and ViroPharma Incorporated. DACART CAPITAL LLC EFTA_R1_01138848 EFTA02295574 References

5M/Unit ■ Available USA Cleantech Fund #1 (USivt ■ $25M Institutional ■ 16 Units @ $625K/Unit ■ Available DAGAR C_APII AL LL, EFTA00506111 David Carter, Managing Director • 25+ years executive-level experience • Chairman, CEO/President - 7 companies • Co-founder - 3 companies • 3 , 1 IPO • >$50

cals business from 2000 to 2003. Prior to joining SmithKline Beecham plc Mr. Pien worked for six years at Abbott Laboratories and for five years at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and ViroPharma Incorporated. DACAR 1 CAPIIAL LLC EFTA00506153 References • Michael Eisenso

5M/Unit ■ Available USA Cleantech Fund #1 (USivt ■ $25M Institutional ■ 16 Units @ $625K/Unit ■ Available DAGAR C_APII AL LL, EFTA00506160 David Carter, Managing Director • 25+ years executive-level experience • Chairman, CEO/President - 7 companies • Co-founder - 3 companies • 3 , 1 IPO •

cals business from 2000 to 2003. Prior to joining SmithKline Beecham plc Mr. Pien worked for six years at Abbott Laboratories and for five years at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and ViroPharma Incorporated. DACAR 1 CAPIIAL LLC EFTA00506199 Advisory Board Andreas Breme